A Phase 3 interventional study of fingolimod and glatiramer acetate in Relapsing-remitting Multiple Sclerosis (RRMS), sponsored by Novartis Pharmaceuticals. Terminated at 130 sites in 7 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-05-28.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing fingolimod in Multiple Sclerosis, Relapsing-Remitting — none open to participants now, 1 under way, none of them phase 3. fingolimod · Multiple Sclerosis, Relapsing-Remitting.
Among the 19 studies testing fingolimod in Multiple Sclerosis, Relapsing-Remitting, this one is the 3rd largest by enrollment, is one of 4 that started in 2012, is one of 5 in phase 3, and was the 12th registered.
618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.
Browse Multiple Sclerosis, Relapsing-Remitting studies →None of the 19 studies testing fingolimod in Multiple Sclerosis, Relapsing-Remitting is open now. The open studies under Multiple Sclerosis, Relapsing-Remitting, anywhere →
fingolimod: first FDA approval 2010 (GILENYA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 60 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 43 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 4 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,064 is above the median of 66 across 437 interventional studies indexed under Multiple Sclerosis, Relapsing-Remitting.
Median enrollment 142 across the 19 interventional studies. Of the 16 that completed or were terminated, 12 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 19 have an industry lead sponsor. The 5 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
34 studies in Multiple Sclerosis, Relapsing-Remitting by Novartis: 1 open now, 4 under way, none of them phase 3. Of 28 finished, 19 (68%) have results posted.
Among the 34 studies in Multiple Sclerosis, Relapsing-Remitting by Novartis, this one is the 3rd largest by enrollment of the 26 interventional ones that give a count, is one of 4 that started in 2012, is one of 5 in phase 3, and was the 16th registered.
Novartis’s Multiple Sclerosis, Relapsing-Remitting studies by the year they started, since 2006.
None of the studies under way reaches primary completion within a year.
Among the 19 studies testing fingolimod in Multiple Sclerosis, Relapsing-Remitting, from their registry updates:
Among Novartis’s 34 in Multiple Sclerosis, Relapsing-Remitting:
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to demonstrate that at least one dose (0.5 mg followed by 0.25 mg) of fingolimod is superior to glatiramer acetate 20 mg SC in reducing the ARR up to 12 months in patients with relapsing-remitting MS
This was a multicenter, randomized, rater- and dose-blinded, study to compare the efficacy and safety of 0.25 mg and 0.5 mg of fingolimod with glatimer acetate 20 mg s.c. in patients with RRMS.
This study consisted of 3 periods:
Treatment groups:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
No is necessary for patients treated with dimethyl fumarate, interferon (IFN) beta, or glatiramer acetate.
Patients being treated with dimethyl fumarate, glatiramer acetate, or IFN beta at the Screening visit can continue drug intake up to the day before Day 1 of this study (i.e., there is no need for a washout period).
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
orally once daily
Drug: fingolimod
orally once daily
Drug: fingolimod
subcutaneous once daily
Drug: glatiramer acetate
capsule
Also known as: FTY720, fingolimod hydrochloride,, Gilenya
subcutaneous injection
Also known as: Copaxone, Glatopa
Confirmed Annualized Relapse Rate
Annualized relapse rate (ARR) was defined as the average number of confirmed relapses per year (i.e., the total number of confirmed relapses divided by the total days in the study multiplied by 365.25). The number of relapses included all the confirmed relapses experienced during the study from first dose to end of study.
Time frame: up to 12 months
New or Newly Enlarging T2 Lesions
Inflammatory activity based on MRI measurement of new/newly enlarged T2 lesion count.
Time frame: At 12 months/end of study
Number of Participants Free of New/Newly Enlarged T2 Lesions
Inflammatory activity based on MRI measurement of new/newly enlarged T2 lesion count.
Time frame: At 12 months/end of study
Change From Baseline in T2 Lesion Volume
Inflammatory activity based on MRI measurement of new/newly enlarged T2 lesion volume
Time frame: Baseline, 12 months/end of study
Gd Enhancing T1 Lesion Count
Inflammatory activity based on MRI measurement of Gd enhancing T1 lesion count
Time frame: At 12 months/end of study
Gd Enhancing T1 Lesion Volume
Inflammatory activity based on MRI measurement of Gd enhancing T1 lesion count
Time frame: Baseline, 12 months/end of study
Percentage of Patients Free of New T1 Hypointense Lesions
Based on MRI measures of new T1 hypointense lesions
Time frame: 12 months
Change From Baseline in TSQM Scales
Treatment Satisfaction Questionnaire for Medication (TSQM) was developed and validated as a general measure for treatment satisfaction. Each scale score was calculated by summing individual items and then transformed to a 0-100 scale. Higher summary scores indicate better satisfaction with study drug.
Time frame: 6 months, 12 months/end of study
Percent Brain Volume Change From Baseline
Using a Central MRI vendor to ensure calibrated MRI scanning equipment across all sites, MRI scans were performed on subjects following the established parameters and transferred to the central vendor for review of quality and assessment/evaluation.
Time frame: Baseline, 12 months, end of study
| Milestone | FTY720 0.5 mg | FTY720 0.25 mg | GA 20 mg |
|---|---|---|---|
| Started | 352 | 370 | 342 |
| Completed | 299 | 310 | 250 |
| Not completed | 53 | 60 | 92 |
| Withdrew: Lack of efficacy | 1 | 6 | 13 |
| Withdrew: Abnormal laboratory value(s) | 3 | 1 | 0 |
| Withdrew: Abnormal test procedure result(s) | 0 | 1 | 0 |
| Withdrew: Administrative problems | 1 | 2 | 5 |
| Withdrew: Adverse event | 16 | 18 | 20 |
| Withdrew: Lost to follow-up | 7 | 19 | 6 |
| Withdrew: Protocol violation | 4 | 0 | 2 |
| Withdrew: Subject no longer requires study drug | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 20 | 12 | 41 |
| Withdrew: Missing study completion crf | 1 | 1 | 4 |
Annualized relapse rate (ARR) was defined as the average number of confirmed relapses per year (i.e., the total number of confirmed relapses divided by the total days in the study multiplied by 365.25). The number of relapses included all the confirmed relapses experienced during the study from first dose to end of study.
| relapses/year | FTY720 0.5 mg | FTY720 0.25 mg | GA 20 mg |
|---|---|---|---|
| Confirmed Annualized Relapse Rate | 0.153 (0.111 to 0.212) | 0.221 (0.168 to 0.290) | 0.258 (0.196 to 0.341) |
Inflammatory activity based on MRI measurement of new/newly enlarged T2 lesion count.
| Lesions | FTY720 0.5 mg | FTY720 0.25 mg | GA 20 mg |
|---|---|---|---|
| New or Newly Enlarging T2 Lesions | 2.6 ± 5.42 | 3.3 ± 6.94 | 5.7 ± 10.71 |
Inflammatory activity based on MRI measurement of new/newly enlarged T2 lesion count.
| Participants | FTY720 0.5 mg | FTY720 0.25 mg | GA 20 mg |
|---|---|---|---|
| Number of Participants Free of New/Newly Enlarged T2 Lesions | 156 | 155 | 96 |
Inflammatory activity based on MRI measurement of new/newly enlarged T2 lesion volume
| cubic centimeters (cc) | FTY720 0.5 mg | FTY720 0.25 mg | GA 20 mg |
|---|---|---|---|
| Change From Baseline in T2 Lesion Volume | -0.14 ± 1.583 | -0.05 ± 2.340 | 0.42 ± 2.305 |
Inflammatory activity based on MRI measurement of Gd enhancing T1 lesion count
| lesions | FTY720 0.5 mg | FTY720 0.25 mg | GA 20 mg |
|---|---|---|---|
| Gd Enhancing T1 Lesion Count | 0.4 ± 1.57 | 0.4 ± 1.56 | 0.9 ± 3.67 |
Inflammatory activity based on MRI measurement of Gd enhancing T1 lesion count
| cubic centimeter | FTY720 0.5 mg | FTY720 0.25 mg | GA 20 mg |
|---|---|---|---|
| Baseline | 0.31 ± 1.067 | 0.32 ± 1.421 | 0.22 ± 0.841 |
| Month 12/end of study | 0.06 ± 0.215 | 0.05 ± 0.181 | 0.12 ± 0.450 |
Based on MRI measures of new T1 hypointense lesions
| Percentage | FTY720 0.5 mg | FTY720 0.25 mg | GA 20 mg |
|---|---|---|---|
| Percentage of Patients Free of New T1 Hypointense Lesions | 55.3 | 52.1 | 44.3 |
Treatment Satisfaction Questionnaire for Medication (TSQM) was developed and validated as a general measure for treatment satisfaction. Each scale score was calculated by summing individual items and then transformed to a 0-100 scale. Higher summary scores indicate better satisfaction with study drug.
| score on a scale | FTY720 0.5 mg | FTY720 0.25 mg | GA 20 mg |
|---|---|---|---|
| Global Satisfaction (Month 6) | 20.8 ± 28.15 | 23.4 ± 27.04 | 14.4 ± 25.42 |
| Global Satisfaction (Month 12) | 19.2 ± 31.87 | 20.5 ± 32.21 | 9.4 ± 30.43 |
| Effectiveness (Month 6) | 15.2 ± 25.96 | 18.2 ± 25.05 | 12.9 ± 23.43 |
| Effectiveness (Month 12) | 16.8 ± 26.85 | 17.9 ± 28.29 | 8.0 ± 27.38 |
| Side Effects (Month 6) | 16.9 ± 31.58 | 18.8 ± 30.63 | 9.3 ± 31.94 |
| Side Effects (Month 12) | 16.2 ± 31.52 | 17.2 ± 32.52 | 7.6 ± 32.76 |
| Convenience (Month 6) | 30.7 ± 25.76 | 26.5 ± 25.93 | 4.4 ± 20.73 |
| Convenience (Month 12) | 29.5 ± 24.42 | 26.5 ± 26.36 | 0.8 ± 25.72 |
Using a Central MRI vendor to ensure calibrated MRI scanning equipment across all sites, MRI scans were performed on subjects following the established parameters and transferred to the central vendor for review of quality and assessment/evaluation.
| Percentages of volume change | FTY720 0.5 mg | FTY720 0.25 mg | GA 20 mg |
|---|---|---|---|
| Percent Brain Volume Change From Baseline | -0.652 ± 0.7810 | -0.636 ± 0.8097 | -0.561 ± 0.7819 |
Collected over Adverse Events (AEs) and Serious AEs (SAEs) were collected during treatment exposure and follow up where: AE summaries on the follow-up set were conducted for time periods defined by days relative to study drug discontinuation: days 1 - 45 after discontinuation, or day 46 or later after drug discontinuation. For SAEs (death and non-fatal ), all SAEs starting after the first dose date, including those starting > 45 days after study drug discontinuation, were included in the safety set summaries.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Fingolimod 0.5 mg | 0/345 (0%) | 25/345 (7.2%) | 214/345 (62%) |
| FTY 0.25 mg | 0/366 (0%) | 32/366 (8.7%) | 245/366 (66.9%) |
| GA 20 mg | 0/324 (0%) | 20/324 (6.2%) | 190/324 (58.6%) |
| All@Patients | 0/1,035 (0%) | 77/1,035 (7.4%) | 649/1,035 (62.7%) |
| Event | Fingolimod 0.5 mg | FTY 0.25 mg | GA 20 mg | All@Patients |
|---|---|---|---|---|
| Multiple sclerosis relapseNervous system disorders | 4/345 | 7/366 | 7/324 | 18/1035 |
| Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 3/345 | 4/366 | 0/324 | 7/1035 |
| HeadacheNervous system disorders | 1/345 | 3/366 | 0/324 | 4/1035 |
| Urinary tract infectionInfections and infestations | 2/345 | 1/366 | 2/324 | 5/1035 |
| SyncopeNervous system disorders | 0/345 | 0/366 | 2/324 | 2/1035 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 2/345 | 0/366 | 0/324 | 2/1035 |
| LeukocytosisBlood and lymphatic system disorders | 0/345 | 2/366 | 0/324 | 2/1035 |
| Gait disturbanceGeneral disorders | 0/345 | 2/366 | 0/324 | 2/1035 |
| SeizureNervous system disorders | 1/345 | 2/366 | 0/324 | 3/1035 |
| Acute myocardial infarctionCardiac disorders | 0/345 | 0/366 | 1/324 | 1/1035 |
| Event | Fingolimod 0.5 mg | FTY 0.25 mg | GA 20 mg | All@Patients |
|---|---|---|---|---|
| HeadacheNervous system disorders | 51/345 | 50/366 | 27/324 | 128/1035 |
| FatigueGeneral disorders | 46/345 | 46/366 | 22/324 | 114/1035 |
| Urinary tract infectionInfections and infestations | 44/345 | 43/366 | 35/324 | 122/1035 |
| Injection site painGeneral disorders | 0/345 | 0/366 | 36/324 | 36/1035 |
| Injection site erythemaGeneral disorders | 0/345 | 0/366 | 34/324 | 34/1035 |
| Upper respiratory tract infectionInfections and infestations | 30/345 | 35/366 | 20/324 | 85/1035 |
| HypertensionVascular disorders | 26/345 | 34/366 | 12/324 | 72/1035 |
| NauseaGastrointestinal disorders | 24/345 | 30/366 | 15/324 | 69/1035 |
| Injection site pruritusGeneral disorders | 0/345 | 0/366 | 26/324 | 26/1035 |
| DizzinessNervous system disorders | 12/345 | 27/366 | 14/324 | 53/1035 |
Ramdomized set: All subjects who were assigned randomization numbers. The subjects in this set were called randomized subjects. This set was used to summarize subject disposition, demographic and baseline characteristics, and protocol deviation information. Subjects were grouped according to randomized treatment.
| Age, Continuous(Years) | FTY720 0.5 mg | FTY720 0.25 mg | GA 20 mg | Total |
|---|---|---|---|---|
| Mean | 40.3 ± 11.12 | 38.9 ± 11.01 | 39.6 ± 10.80 | 39.6 ± 10.98 |
| Sex: Female, Male(Participants) | FTY720 0.5 mg | FTY720 0.25 mg | GA 20 mg | Total |
|---|---|---|---|---|
| Female | 264 | 276 | 252 | 792 |
| Male | 88 | 94 | 90 | 272 |
| Race/Ethnicity, Customized(Participants) | FTY720 0.5 mg | FTY720 0.25 mg | GA 20 mg | Total |
|---|---|---|---|---|
| Caucasian | 268 | 279 | 243 | 790 |
| Black | 34 | 43 | 41 | 118 |
| Asian | 0 | 1 | 0 | 1 |
| Native American | 8 | 7 | 9 | 24 |
| Pacific Islander | 0 | 1 | 0 | 1 |
| Other | 42 | 39 | 49 | 130 |
Showing the first 100 of 130 sites across 7 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Data sharing details ↗ · www.clinicalstudydatarequest.com
Ran from Aug 2012 to primary completion in Apr 2018, 68 months.
Results were first posted in May 2019, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fingolimod
Multiple Sclerosis, Relapsing-Remitting →